|
Sub-category:
Melanoma
Category:
Melanoma
Meeting:
2008 ASCO Annual Meeting
Abstract No:
20016
Citation:
J Clin Oncol 26: 2008 (May 20 suppl; abstr 20016)
Author(s):
D. Taylor, J. Nyambose, K. Kulig, C. C. Earle, D. Thompson
Abstract:
Background: Rankings of different cancer types by annual numbers of deaths provide important, albeit incomplete, data on overall impact of mortality. Because some cancers primarily affect younger people and have short survival, their impact on years of life lost (YLL) and lifetime earnings lost (LEL) is greater than that suggested by raw numbers of attributable deaths. To illustrate, we compared YLL and LEL for advanced stage malignant melanoma to seven tumor types also affecting both sexes. Methods: All fatal cases of advanced-stage cancer were identified in the most recent U.S. Surveillance Epidemiology and End Results (SEER) cancer registry (1995-2004). YLL due to melanoma was compared with other advanced-stage cancers that affect both sexes, including tumors of the colon /rectum, oral cavity/pharynx, brain/other nervous system (ONS), lung/bronchus, liver/intrahepatic bile duct, pancreas, and kidney/renal pelvis. Median survival was assessed using SEER*Stat software. YLL was calculated by subtracting the median survival since diagnosis from the individual's life expectancy without cancer at the time of diagnosis, based on the 2003 U.S. Life Tables. Total YLL was calculated by summing the products of YLL and deaths in each age group; average YLL (AYLL) by dividing total YLL by total deaths; total LEL by multiplying LEL by deaths for each tumor type; and average LEL by dividing total LEL by total deaths. LEL were based on 2005 U.S. Census Bureau Historical Income Tables. Results: Malignant melanoma had both the highest estimated AYLL (22.1 years) and average LEL ($831,000) versus other cancers (Table). Conclusions: The impact of malignant melanoma on average years of life lost and lifetime earnings lost is greater than that of the other cancers assessed. Because melanoma often strikes younger people, and because current therapies do not significantly extend survival, the humanistic and societal burden is greater than that of the other tumor types. Average years of life lost (AYLL) and average lifetime earnings lost (LEL) | Cancer Site | AYLL | Average LEL | | Melanoma of the skin | 22.1 | $831,000 | | Liver and intrahepatic bile duct | 21.7 | $769,000 | | Oral Cavity & Pharynx | 20.3 | $784,000 | | Brain and Other Nervous Systems | 19.7 | $757,000 | | Kidney and Renal Pelvis | 19.2 | $699,000 | | Lung and Bronchus | 18.2 | $652,000 | | Pancreas | 17.5 | $612,000 | | Colon and Rectum | 17.1 | $622,000 |
Abstract Disclosures
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy
and are designated with a caret symbol (^) here and in the print version.
 Associated Presentation(s):
Other Abstracts in this Sub-Category:
Abstracts by D. Taylor :
Presentations by D. Taylor :
Educational Book Manuscripts by D. Taylor :
|
